August 12, 2016

Breast Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email

A Phase III, Multicenter, Randomized,Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor-Postitive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed During or after CDK4/6 Inhibitor and Endocrine Combination Therapy

Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)

A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with HER2 Low Breast Cancer (Cornerstone001)

A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant plus Everolimus Compared with Exemestane plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Return to Clinical Trials at GCC